(NASDAQ: EOLS) Evolus's forecast annual revenue growth rate of 28.57% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 3.99%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Evolus's revenue in 2025 is $275,463,000.On average, 3 Wall Street analysts forecast EOLS's revenue for 2025 to be $22,567,100,906, with the lowest EOLS revenue forecast at $22,334,344,030, and the highest EOLS revenue forecast at $22,806,950,097. On average, 3 Wall Street analysts forecast EOLS's revenue for 2026 to be $29,684,561,176, with the lowest EOLS revenue forecast at $28,646,504,193, and the highest EOLS revenue forecast at $30,213,261,005.
In 2027, EOLS is forecast to generate $37,938,081,323 in revenue, with the lowest revenue forecast at $36,280,413,930 and the highest revenue forecast at $38,990,967,692.